Peptide receptor radionuclide therapy for advanced neuroendocrine tumors that affect pancreas, GI tract by Mike Bassett, Contributing Writer, MedPage Today April 30, 2020 MedpageToday email article
The most significant recent development in the treatment of patients with metastasized or inoperable neuroendocrine tumors (NETs) has been the FDA approval of peptide receptor radionuclide therapy (PRRT). The treatment has a history dating back to the early 1990s.
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
